Patrys CEO and MD, Dr James Campbell, was recently featured as one of Insights Care Magazine’s Top 10 Influential Healthcare Leaders in 2022.
The feature recounts James’ journey into biotech, and how Patrys’ deoxymab technology is shaping up to be a transformative cancer treatment.
Here’s an excerpt from the Q&A:
“In 2015, I joined Patrys as its CEO to identify and acquire new technology that could advance the company’s mission of developing novel antibody-based cancer therapies. This is what has become our deoxymab platform. By 2023, we will be able to realise the work that has progressed for so long with the first clinical trial of our anti-cancer antibody, PAT-DX1.”